ROS1 and non-small cell lung carcinoma: In conclusion, the study fully validates the feasibility of integrating a DNA (SiRe®) and RNA (SiRe fusion) primer pool in an Ampliseq based approach to cover all the clinically relevant NSCLC alterations (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK, and METex14) simultaneously in a single run, regardless of the small sample size of available tissue.